Dr. Kimberly Meza's abstract Nuvisertib (TP-3654) and Dordaviprone (ONC201) synergize to reduce renal cell carcinoma cell viability has been accepted for poster presentation at the AACR Special Conference in Cancer Research: Innovations in Kidney Cancer Research: From Molecular Insights to Therapeutic Breakthroughs, being held from March 13 – 16, 2026, at the W. Philadelphia Hotel, in Philadelphia, Pennsylvania.